Oncotrail Leader Labs

Oncotrail test is designed for specific cancers, i.e. Breast, Colon, GI, Melanoma, Prostate, and Sarcoma. The purpose of the test is to benchmark the aggressiveness of these tumors as well as to track the current management of these cancers. We use this test to monitor these cancers during chemotherapy as well as when a patient is in remission. It checks for Circulating Tumor Cells (CTCs) and provides genetic insights into the nature of the CTCs.

Oncotrail RGCC isn’t used as a primary diagnostic test to confirm a cancer diagnosis but provides essential information on the effectiveness of current cancer treatments. Follow-up tests can also be used to monitor a patient’s health and assess the risk of relapse.

How does Oncotrail RGCC work?

• A blood sample is analyzed to identify the presence and concentration of CTCs in the blood. This gives us an idea of the trend of cancer.
• Oncotrail RGCC also allows for immunophenotyping of the cancer cells, meaning that we can elucidate the nature of the cancer cells which would give us information on how aggressive each cell is.
• This test serves as an assessment of the current status of specific types of cancer.

Why choose the Oncotrail RGCC test?

• Oncotrail RGCC has undergone rigorous evaluation to ensure high sensitivity and specificity.
• Through high-precision techniques, the test is used to monitor the effectiveness of a particular cancer treatment. This objectively provides information on how well the treatment is going.
• This non-invasive tracking of the cancer status notifies the treating physician whether there is a need to adjust the current treatment plan. This helps ensure that the best treatment plan is followed in a timely manner.